ClinicalTrials.gg
CompletedNCT03850782TRITONUpdated Nov 13, 2026Results posted

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

A Phase 3 interventional study of Bimatoprost (SR) in Open-Angle Glaucoma and Ocular Hypertension, sponsored by AbbVie. Completed at 108 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

How we know

Updated Nov 13, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
515
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing bimatoprost in Glaucoma, Open-Angle — 2 open to participants now, 2 under way, 1 of them phase 3. Bimatoprost · Glaucoma, Open-Angle.

Enrollment
7th of 29
515 · median 169
Started
2019
with 1 other
Phase 3
9 of 29
1 open now
Registered
24th of 29
by date
Lead sponsor
4 of 29
AbbVie

Among the 29 studies testing bimatoprost in Glaucoma, Open-Angle, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 3, and was the 24th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 29 studies testing bimatoprost in Glaucoma, Open-Angle are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bimatoprost

Bimatoprost: first FDA approval 2001 (LUMIGAN), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing bimatoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.

03

Conditions studied

  • Open-Angle Glaucoma
  • Ocular Hypertension

Keywords

  • Open-Angle Glaucoma (OAG)
  • Ocular Hypertension (OHT)
  • Bimatoprost
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment.

Exclusion criteria

Exclusion Criteria:

  • Concurrent or anticipated enrollment in another drug or device study or participation in such a study within 2 months prior to enrolling in this study.
  • Previous administration with Bimatoprost SR in the study eye.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
515 participants (actual)

Study arms

  • Experimental
    Bimatoprost SR - Dose A

    Study Eye: Participants will receive 1 - 3 Cycles of Bimatoprost SR administrations of Dose A Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or one administration of Bimatoprost SR.

    Drug: Bimatoprost (SR)

  • Experimental
    Bimatoprost SR - Dose B

    Study Eye: Participants received 1 - 3 Cycles of Bimatoprost SR administrations of Dose B Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or one administration of Bimatoprost SR.

    Drug: Bimatoprost (SR)

Interventions

  • DrugBimatoprostStudies of BimatoprostBimatoprost pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Study Eye: Cycles 1 - 3 administrations through the PRN treatment period. Fellow Eye: Standard of care or Bimatoprost SR.

06

What researchers measure

Primary outcomes

  1. Time to Retreatment or Rescue Administered for Intraocular Pressure (IOP)

    The duration of effect for Bimatoprost SR was evaluated by assessing the time to second administration of Bimatoprost SR or first rescue treatment (i.e., initiation of intermittent \[use of rescue IOP-lowering medication until the subject became eligible for and received an additional Bimatoprost SR administration\] or permanent rescue treatment), whichever occurred first, after the first administration in the study eye (SE).

    Time frame: Up to 48 months

  2. Probability of Not Receiving Second Administration or Rescue

    The Kaplan-Meier method was used to estimate the cumulative survival probabilities (i.e., probability of not receiving the re-administration or rescue treatment) at time intervals across the duration of the study.

    Time frame: Up to 48 months

  3. Number of Patients Experiencing a Treatment Emergent Adverse Event (TEAE)

    The number of patients who experienced one or more TEAE during the 48 month treatment period.

    Time frame: Baseline up to 48 months

07

Results

Posted Nov 13, 2026

Participant flow

Participant flow — Overall Study
Milestone10 ug Bimatoprost SR15 ug Bimatoprost SR
Started44662
Number of subjects treated44162
Number of subjects enrolled but not treated50
Completed36350
Not completed8312
Withdrew: Adverse event164
Withdrew: Lack of efficacy20
Withdrew: Withdrawal by subject326
Withdrew: Lost to follow-up150
Withdrew: Death10
Withdrew: Progressive disease10
Withdrew: Protocol violation10
Withdrew: Not disclosed142
Withdrew: Subjects with missing study completion status (completed study required last visit of month 48)10

Outcome measures

PrimaryTime to Retreatment or Rescue Administered for Intraocular Pressure (IOP)

The duration of effect for Bimatoprost SR was evaluated by assessing the time to second administration of Bimatoprost SR or first rescue treatment (i.e., initiation of intermittent \[use of rescue IOP-lowering medication until the subject became eligible for and received an additional Bimatoprost SR administration\] or permanent rescue treatment), whichever occurred first, after the first administration in the study eye (SE).

Time frame:
Up to 48 months
Reported as:
Median · days
Time to Retreatment or Rescue Administered for Intraocular Pressure (IOP)
days10 ug Bimatoprost SR15 ug Bimatoprost SR
Time to Retreatment or Rescue Administered for Intraocular Pressure (IOP)421 (374 to 488)365 (200 to 476)
PrimaryProbability of Not Receiving Second Administration or Rescue

The Kaplan-Meier method was used to estimate the cumulative survival probabilities (i.e., probability of not receiving the re-administration or rescue treatment) at time intervals across the duration of the study.

Time frame:
Up to 48 months
Reported as:
Number · cumulative probability
Probability of Not Receiving Second Administration or Rescue
cumulative probability10 ug Bimatoprost SR15 ug Bimatoprost SR
180 Days0.752 (0.709 to 0.790)0.707 (0.575 to 0.804)
360 Days0.589 (0.541 to 0.634)0.522 (0.390 to 0.639)
540 Days0.409 (0.361 to 0.456)0.357 (0.236 to 0.480)
720 Days0.313 (0.268 to 0.359)0.301 (0.188 to 0.422)
900 Days0.268 (0.225 to 0.313)0.301 (0.188 to 0.422)
1080 Days0.254 (0.212 to 0.299)0.251 (0.143 to 0.374)
1260 Days0.226 (0.183 to 0.272)0.251 (0.143 to 0.374)
1440 Days0.226 (0.183 to 0.272)0.251 (0.143 to 0.374)
PrimaryNumber of Patients Experiencing a Treatment Emergent Adverse Event (TEAE)

The number of patients who experienced one or more TEAE during the 48 month treatment period.

Time frame:
Baseline up to 48 months
Reported as:
Count of participants · Participants
Number of Patients Experiencing a Treatment Emergent Adverse Event (TEAE)
Participants10 ug Bimatoprost SR15 ug Bimatoprost SR
Number of Patients Experiencing a Treatment Emergent Adverse Event (TEAE)35654

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from time informed consent was signed to the end of study. The median time on follow-up was 1119.5 days for the 10 ug Bimatoprost SR group and 1242 days for the 15 ug Bimatoprost SR group.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10 ug Bimatoprost SR7/446 (1.6%)80/446 (17.9%)278/446 (62.3%)
15 ug Bimatoprost SR2/62 (3.2%)12/62 (19.4%)40/62 (64.5%)
Most frequent serious events
Showing 10 of 123
Most frequent serious events
Event10 ug Bimatoprost SR15 ug Bimatoprost SR
CORNEAL OEDEMAEye disorders3/4463/62
FALLInjury, poisoning and procedural complications5/4462/62
CORNEAL ENDOTHELIAL CELL LOSSEye disorders3/4461/62
INTESTINAL PERFORATIONGastrointestinal disorders0/4461/62
NAUSEAGastrointestinal disorders0/4461/62
RECTAL PERFORATIONGastrointestinal disorders0/4461/62
VOMITINGGastrointestinal disorders0/4461/62
DEATHGeneral disorders2/4461/62
COVID-19Infections and infestations2/4461/62
COVID-19 PNEUMONIAInfections and infestations0/4461/62
Most frequent other events
Showing 10 of 19
Most frequent other events
Event10 ug Bimatoprost SR15 ug Bimatoprost SR
CONJUNCTIVAL HYPERAEMIAEye disorders89/44612/62
INTRAOCULAR PRESSURE INCREASEDInvestigations88/4469/62
CORNEAL ENDOTHELIAL CELL LOSSEye disorders66/44612/62
DRY EYEEye disorders41/4468/62
HYPERTENSIONVascular disorders45/4467/62
VISUAL FIELD DEFECTEye disorders26/4466/62
COVID-19Infections and infestations41/4464/62
EYE PAINEye disorders19/4465/62
CONJUNCTIVITISInfections and infestations20/4465/62
ARTHRALGIAMusculoskeletal and connective tissue disorders6/4465/62

Baseline characteristics

Full Analysis Set

Age, Continuous
Age, Continuous(years)10 ug Bimatoprost SR15 ug Bimatoprost SRTotal
Mean62.5 ± 10.8967.5 ± 11.0165 ± 10.95
Age, Customized
Age, Customized(participants)10 ug Bimatoprost SR15 ug Bimatoprost SRTotal
< 45 years22325
45 - 65 years23524259
> 65 years18435219
Sex: Female, Male
Sex: Female, Male(Participants)10 ug Bimatoprost SR15 ug Bimatoprost SRTotal
Female23931270
Male20231233
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)10 ug Bimatoprost SR15 ug Bimatoprost SRTotal
Hispanic or Latino50555
Not Hispanic or Latino39157448
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)10 ug Bimatoprost SR15 ug Bimatoprost SRTotal
American Indian or Alaska Native314
Asian336
Native Hawaiian or Other Pacific Islander101
Black or African American66571
White36053413
More than one race808
Unknown or Not Reported000
08

Study locations

108 sites
  • Horizon Eye Specialists & Lasik Centers /ID# 235240
    Sun City, Arizona 85351, United States
  • Atlantis Eye Care /ID# 235530
    Huntington Beach, California 92647, United States
  • Lakeside Vision Center /ID# 234970
    Irvine, California 92604, United States
  • Global Research Foundation /ID# 237350
    Los Angeles, California 90041-1718, United States
  • The Eye Research Foundation /ID# 234521
    Newport Beach, California 92663-3637, United States
  • Byers Eye Institute Stanford /ID# 235544
    Palo Alto, California 94303, United States
  • Foothill Eye Institute /ID# 235640
    Pasadena, California 91107, United States
  • Connecticut Eye Consultants P.C. /ID# 234981
    Danbury, Connecticut 06810, United States
  • Advanced Research, LLC /ID# 236045
    Deerfield Beach, Florida 33064-1342, United States
  • Segal Drug Trials, Inc /ID# 235784
    Delray Beach, Florida 33484, United States
  • International Research Center /ID# 238050
    Tampa, Florida 33603, United States
  • Thomas Eye Group PC /ID# 235737
    Sandy Springs, Georgia 30328, United States
  • Indiana University - Glick Eye Institute /ID# 235886
    Indianapolis, Indiana 46202, United States
  • Retina Partners Midwest, PC /ID# 237876
    Indianapolis, Indiana 46290, United States
  • Tulane University School of Medicine /ID# 237632
    New Orleans, Louisiana 70112, United States
  • Ophthalmic Consultants of Boston /ID# 236534
    Boston, Massachusetts 02129, United States
  • Clinical Eye Research of Boston LLC /ID# 234966
    Winchester, Massachusetts 01890, United States
  • University of Michigan, Kellogg Eye Center /ID# 236496
    Ann Arbor, Michigan 48105, United States
  • Fraser Eye Center /ID# 235790
    Fraser, Michigan 48026, United States
  • Silverstein Eye Centers /ID# 237881
    Kansas City, Missouri 64034, United States
  • Moyes Eye Centers /ID# 234989
    Kansas City, Missouri 64154, United States
  • Alterman Modi & Wolter /ID# 235248
    Poughkeepsie, New York 12603-2455, United States
  • The Ohio State University /ID# 236790
    Columbus, Ohio 43210-1257, United States
  • AMA Eyes Research Institute /ID# 235542
    Marysville, Ohio 43040, United States
  • Dean McGee Eye Institute /ID# 236823
    Oklahoma City, Oklahoma 73104, United States
  • Oklahoma Eye Surgeons /ID# 235849
    Oklahoma City, Oklahoma 73112, United States
  • Drs Fine Hoffman & Sims LLC /ID# 235918
    Eugene, Oregon 97401, United States
  • Ophthalmic Partners, PC /ID# 235741
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Scott and Christie and Associates /ID# 234593
    Cranberry Township, Pennsylvania 16066, United States
  • Black Hills Regional Eye Institute /ID# 235075
    Rapid City, South Dakota 57701, United States
  • Vance Thompson Vision /ID# 235072
    Sioux Falls, South Dakota 57108, United States
  • Eye Specialty Group /ID# 235721
    Memphis, Tennessee 38120, United States
  • Vanderbilt University Medical Center /ID# 237177
    Nashville, Tennessee 37232-0011, United States
  • Advancing Vision Research /ID# 236681
    Smyrna, Tennessee 37167, United States
  • ATX Clinical Trials Inc. dba Keystone Research /ID# 235868
    Austin, Texas 78731, United States
  • Medical Center Ophthalmology Associates - Keystone Research /ID# 235787
    San Antonio, Texas 78240, United States
  • Southern Utah Medical Research /ID# 235602
    St. George, Utah 84790, United States
  • Piedmont Eye Center /ID# 234534
    Lynchburg, Virginia 24502, United States
  • Consultorio Oftalmologico Dr. Fabian Lerner /ID# 235855
    CABA, Buenos Aires 1122, Argentina
  • Hospital Universitario Austral /ID# 237727
    Pilar, Buenos Aires 1629, Argentina
  • Centro oftalmologico Dr Charles /ID# 235881
    Ciudad de Buenos Aires, Buenos Aires F.D. 1116, Argentina
  • Oftalmología Global /ID# 239187
    Rosario, Santa Fe Province 2000, Argentina
  • Hospital Italiano /ID# 235851
    Buenos Aires, 1181, Argentina
  • Centro Privado de Ojos /ID# 241283
    Ciudad Autonoma Buenos Aires, 1033, Argentina
  • Oftar Mendoza /ID# 240535
    Mendoza, 1019, Argentina
  • Eye Surgery Associates /ID# 235873
    East Melbourne, Victoria 3002, Australia
  • Multiprofile Hospital for Active Treatment "Lozenetz" /ID# 244053
    Sofiya, Sofia 1407, Bulgaria
  • Diagnostic Consultative Center Aleksandrovska /ID# 238105
    Sofiya, Sofia 1431, Bulgaria
  • Medical Center Oxycom Burgas /ID# 235580
    Burgas, 8008, Bulgaria
  • UMHAT Sveti Georgi /ID# 237027
    Plovdiv, 4002, Bulgaria
  • MHAT Hadzhi Dimitar /ID# 238248
    Sliven, 8800, Bulgaria
  • MHAT Dr. Bratan Shukerov /ID# 235498
    Smolyan, 4700, Bulgaria
  • Medical center for eye healt Focus Ltd /ID# 235575
    Sofia, 1303, Bulgaria
  • Pentagram Eye Hospital /ID# 235813
    Sofia, 1309, Bulgaria
  • Specialized Hospital for Active Treatment in Ocular Diseases "Zrenie" /ID# 235500
    Sofia, 1408, Bulgaria
  • St. Sofia Hospital /ID# 235525
    Sofia, 1618, Bulgaria
  • Medical Center -Verea /ID# 235494
    Stara Zagora, 6000, Bulgaria
  • Medical center Orfey /ID# 237344
    Stara Zagora, 6000, Bulgaria
  • MHAT Trakia /ID# 238137
    Stara Zagora, 6004, Bulgaria
  • Specialized Ophthalmological Hospital for Active Treatment - Varna /ID# 235962
    Varna, 9002, Bulgaria
  • Vseobecna Fakultni Nemocnice v Praze /ID# 234422
    Prague, Praha 17 128 00, Czechia
  • Ocni klinika Pardubice /ID# 235944
    Pardubice, 530 02, Czechia
  • Fakultni nemocnice Kralovske Vinohrady /ID# 234323
    Prague, 100 34, Czechia
  • Rigshospitalet Glostrup /ID# 235743
    Glostrup Municipality, Capital Region 2600, Denmark
  • Universitatsklinikum Freiburg /ID# 238048
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Universitaetsmedizin Goettingen /ID# 237377
    Göttingen, Lower Saxony 37075, Germany
  • Universitaetsmedizin Rostock /ID# 237263
    Rostock, Mecklenburg-Vorpommern 18057, Germany
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 237069
    Kiel, Schleswig-Holstein 24105, Germany
  • Klinikum Dresden Friedrichstadt /ID# 235308
    Dresden, 01067, Germany
  • Asklepios Kinik Nord - Heidberg Augenklinik /ID# 235955
    Hamburg, 22417, Germany
  • St. Franziskus-Hospital /ID# 237714
    Münster, 48145, Germany
  • Dietrich-Bonhoeffer-Klinikum /ID# 235262
    Neubrandenburg, 17036, Germany
  • Duplicate_Augenzentrum Dr Hamacher /ID# 235537
    Starnberg, 82319, Germany
  • Gyongyosi Bugat Pal Korhaz /ID# 238144
    Gyöngyös, Heves County 3200, Hungary
  • Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 237383
    Szombathely, Vas County 9700, Hungary
  • Budapest Retina Intezet /ID# 235950
    Budapest, 1133, Hungary
  • Jahn Ferenc Del-pesti Korhaz es Rendelointezet /ID# 237111
    Budapest, 1204, Hungary
  • Royal Victoria Eye and Ear Hospital /ID# 235546
    Dublin, 2, Ireland
  • Institute of Eye Surgery /ID# 235547
    Waterford, X91 DH9W, Ireland
  • University of Catanzaro /ID# 238066
    Catanzaro, Calabria 88100, Italy
  • Sapienza University of Rome - Polo Pontino /ID# 237451
    Terracina, Latina 04019, Italy
  • Duplicate_Eye Clinic University of Catania /ID# 235573
    Catania, 95123, Italy
  • Duplicate_Ospedale Ss. Annunziata /ID# 236587
    Chieti, 66100, Italy
  • Fondazione IRCCS Policlinico San Matteo /ID# 236909
    Pavia, 27100, Italy
  • University of Perugia /ID# 235811
    Perugia, 06156, Italy
  • Fondazione Bietti - Ospedale Britannico /ID# 235495
    Rome, 00184, Italy
  • Southern Eye Specialists /ID# 236080
    Christchurch, Canterbury 8013, New Zealand
  • Capital Eye Specialists /ID# 236112
    Wellington, 6011, New Zealand
  • Wojskowy Instytut Medyczny /ID# 237031
    Warsaw, Masovian Voivodeship 04-349, Poland
  • Optimum Profesorskie Centrum Okulistyki SP.z.o.o. /ID# 237076
    Gdansk, Pomeranian Voivodeship 80-809, Poland
  • Centrum Diagnostyki i Mikrochirurgii Oka - LENS sp. z o.o /ID# 235928
    Olsztyn, Warmian-Masurian Voivodeship 10-424, Poland
  • Gabinet Okulistyczny Edward Wylegala /ID# 235946
    Katowice, 40-594, Poland
  • Medical Center Julianow /ID# 235961
    Lodz, Łódź Voivodeship 91-485, Poland
  • S. Fyodorov Eye Microsurgery Federal State Institution /ID# 235984
    Novosibirsk, Novosibirsk Oblast 630071, Russia
  • Pretoria Eye Institute - Private Practice /ID# 235658
    Pretoria, Gauteng 0083, South Africa
  • Somerset Eye Specialist Medical & Surgical Centre /ID# 235540
    Somerset West, Western Cape 7130, South Africa
  • Norrlands University hospital /ID# 237553
    Umeå, Västerbotten County 581 85, Sweden
  • Addenbrookes Hospital /ID# 238255
    Cambridge, Cambridgeshire CB2 2QQ, United Kingdom
  • Mid Essex Hospitals NHS Trust /ID# 237776
    Chelmsford, Essex CM1 7ET, United Kingdom
  • The Princess Alexandra NHS Trust /ID# 234433
    Harlow, Essex CM20 1QX, United Kingdom

Showing the first 100 of 108 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Silverstein SM, Oddone F, Kolko M, Brinkmann CK, Christie WC, Bicket AK, Gous PNJ, Luebke J, Maram J, Nguyen A, Craven ER, Pu Y, Jiao J, Bejanian M, Robinson MR; TRITON Study Group. Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON). Drugs. 2025 Apr;85(4):557-570. doi: 10.1007/s40265-025-02154-4. Epub 2025 Feb 22. PubMed 39985740 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Aug 2025, 77 months.

Results were first posted in Nov 2026, 1 year 3 months after primary completion.

Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 77 months is above that.

Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2019
First posted
Feb 22, 2019
StartActual
Feb 28, 2019
Primary completionActual
Aug 8, 2025
CompletionActual
Aug 8, 2025
Results first posted
Nov 13, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 13, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (1 Czechia, 1 Germany)
  • Vseobecna Fakultni Nemocnice v Praze /ID# 234422 · Prague, Czechia
  • Duplicate_Augenzentrum Dr Hamacher /ID# 235537 · Starnberg, Germany
Show 2 removed
  • Všeobecná Fakultní Nemocnice v Praze /ID# 234422 · Prague, Czechia
  • Augenzentrum Dr Hamacher /ID# 235537 · Starnberg, Germany
Nov 13, 2026
Primary outcomes
2 edited, 1 added
What changed in the outcomes
  • EditedTime to Retreatment or rescue administeredRescue Administered for Intraocular Pressure (IOP)Time frame: Up to 48 months
  • EditedNumber of patients experiencingPatients Experiencing a treatment emergent adverse eventTreatment Emergent Adverse Event (TEAE)Time frame: Baseline up to 48 months
  • AddedProbability of Not Receiving Second Administration or RescueTime frame: Up to 48 months
Nov 13, 2026
Documents
Show all 1 update
  1. Nov 13, 2026
    Results posted
    2 sites added, 2 sites removed
    Show 2 added (1 Czechia, 1 Germany)
    • Vseobecna Fakultni Nemocnice v Praze /ID# 234422 · Prague, Czechia
    • Duplicate_Augenzentrum Dr Hamacher /ID# 235537 · Starnberg, Germany
    Show 2 removed
    • Všeobecná Fakultní Nemocnice v Praze /ID# 234422 · Prague, Czechia
    • Augenzentrum Dr Hamacher /ID# 235537 · Starnberg, Germany
    Primary outcomes 2 edited, 1 added
    What changed in the outcomes
    • EditedTime to Retreatment or rescue administeredRescue Administered for Intraocular Pressure (IOP)Time frame: Up to 48 months
    • EditedNumber of patients experiencingPatients Experiencing a treatment emergent adverse eventTreatment Emergent Adverse Event (TEAE)Time frame: Baseline up to 48 months
    • AddedProbability of Not Receiving Second Administration or RescueTime frame: Up to 48 months
    + 4 other changes: identifiers, verification date, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03850782
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 22, 2019
Start date
Feb 28, 2019
Primary completion
Aug 8, 2025
Completion
Aug 8, 2025
Results posted
Nov 13, 2026
Last update
Nov 13, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimatoprost

Start the discussion